ClinicalTrials.gg
RecruitingNCT06211569PrevADEOSEUpdated Apr 16, 2026

Study of the Prevalence of Endometriosis and Adenomyosis

An observational study in Elective Fertility Preservation, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to female participants aged 29 Years to 37 Years. Per ClinicalTrials.gov, last updated 2026-04-16.

Sponsored by Assistance Publique - Hôpitaux de Paris · Observational

How we know

From the registry’s dates

  • Started Apr 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
400
Ages
29 Years to 37 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 12 studies in Endometriosis by Assistance Publique - Hôpitaux de Paris — 6 open to participants now, 7 under way, none of them phase 3. Endometriosis · Assistance Publique - Hôpitaux de Paris.

Started
2024
the only one that year
Observational
6 of 12
3 open now
Registered
8th of 12
by date

Among the 12 studies in Endometriosis by Assistance Publique - Hôpitaux de Paris, this one is the only one that started in 2024, is one of 6 observational ones, and was the 8th registered.

Endometriosis

924 studies on the registry are indexed under Endometriosis; 268 are open to participants now.

Browse Endometriosis studies →

Open to participants now

6 of the 12 studies in Endometriosis by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 180 Endometriosis studies recruiting now, 53 (29%) set no upper age limit and 125 (69%) stop at 75 or younger; 18 take children under 18; 39 take healthy volunteers.

This study: 29 Years to 37 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Endometriosis by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

Our study aims to assess the prevalence of adenomyosis and endometriosis in patients consulting for elective fertility preservation through the diagnosis of these pathologies by transvaginal pelvic ultrasound. Imaging data will be compared with clinical data (patient characteristics, clinical symptoms) as well as the assessment of anxiety, depression, and quality of life collected from the women.

Read the detailed description

Adenomyosis and endometriosis are two heterogeneous benign gynecological pathologies, in terms of the presence of diverse phenotypes and their symptomatic presentation: While some women are entirely asymptomatic, others experience pelvic pain, infertility, or abnormal uterine bleeding.

Assessing the prevalence of these two pathologies is challenging: On the one hand, a significant number of women are asymptomatic and not considered in the calculation; on the other hand, endometriosis and adenomyosis are often underdiagnosed, leading to delayed diagnosis.

Endometriosis and adenomyosis are frequently associated. Improving knowledge about the epidemiology of endometriosis and adenomyosis is crucial as both are major causes of clinical symptoms that adversely affect the quality of life in numerous women. This is a significant issue for women's health due to the associated suffering, numerous surgical interventions, healthcare expenses, and the suggested link with pathologies that may affect other organs. Understanding the disease could lead to improved treatment and the development of preventive strategies.

Therefore, it is urgent to determine the frequency of endometriosis and adenomyosis, as well as the correlation between women's characteristics, especially their clinical symptoms, and different phenotypes. In order to assess the prevalence of adenomyosis and endometriosis in a population of women of reproductive age, the investigators intend to conduct this single-center study focusing on patients consulting for non-medical fertility preservation.

03

Conditions studied

  • Elective Fertility Preservation

Keywords

  • Endometriosis
  • Adenomyosis
  • Prevalence
  • Elective fertility preservation
  • Transvaginal pelvic ultrasound
04

Who can participate

Ages eligible
29 Years to 37 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Women of childbearing age, not pregnant, consulting for non-medical oocyte self-preservation

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Woman aged between 29 and 37
  • Consultant for non-medical fertility preservation in the Reproductive Medicine Unit Port Royal, Cochin
  • Informed and not opposed to this research
  • Affiliated to a social security scheme

Exclusion criteria

Exclusion Criteria:

  • Pregnant women
  • Refusing to take part in the study
  • Under court protection, curatorship or guardianship
  • Women with a known malformation of the genital tract
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
400 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients

    Women of childbearing age, consulting for elective fertility preservation

    Other: Usual follow-up

Interventions

  • OtherUsual follow-up

    Usual follow-up

06

What researchers measure

Primary outcomes

  1. Transvaginal pelvic ultrasound

    Search for endometriosis and adenomyosis on transvaginal pelvic ultrasound and characterisation of lesions.

    Time frame: Up to month 6

Secondary outcomes

  1. Self-questionnaire

    Socio-demographic data

    Time frame: Inclusion

  2. Self-questionnaire

    Medical history

    Time frame: Inclusion

  3. Quality of life assessment (WHO-QOL-BREF)

    Between 26 (Poor quality of life) and 130 (good quality of life)

    Time frame: Inclusion

  4. Hospital Anxiety and Depression Scale (HADS)

    2 scores between 0 (No anxiety or depression) and 21 (lots of anxiety and depression)

    Time frame: Inclusion

07

Study locations

1 of 1 sites recruiting
  • Gynécologie Obstétrique II et médecine de la reproduction, Hôpital Cochin, Port Royal
    Paris, Île-de-France Region 75014, France
    Recruiting
    • Mathilde BOURDON, MD · Contactmathilde.bourdon@aphp.fr · 00331 58 41 39 20
    • Pietro SANTULLI · Sub investigator
    • Mathilde BOURDON · Principal investigator
08

References and documents

Publications

  • Bird CC, McElin TW, Manalo-Estrella P. The elusive adenomyosis of the uterus--revisited. Am J Obstet Gynecol. 1972 Mar;112(5):583-93. doi: 10.1016/0002-9378(72)90781-8. No abstract available. PubMed 5059589 ↗
  • Bordonne C, Puntonet J, Maitrot-Mantelet L, Bourdon M, Marcellin L, Dion E, Plu-Bureau G, Santulli P, Chapron C. Imaging for evaluation of endometriosis and adenomyosis. Minerva Obstet Gynecol. 2021 Jun;73(3):290-303. doi: 10.23736/S2724-606X.21.04710-9. PubMed 34008384 ↗
  • Bourdon M, Oliveira J, Marcellin L, Santulli P, Bordonne C, Maitrot Mantelet L, Millischer AE, Plu Bureau G, Chapron C. Adenomyosis of the inner and outer myometrium are associated with different clinical profiles. Hum Reprod. 2021 Jan 25;36(2):349-357. doi: 10.1093/humrep/deaa307. PubMed 33491057 ↗
  • Bourdon M, Santulli P, Marcellin L, Maignien C, Maitrot-Mantelet L, Bordonne C, Plu Bureau G, Chapron C. Adenomyosis: An update regarding its diagnosis and clinical features. J Gynecol Obstet Hum Reprod. 2021 Dec;50(10):102228. doi: 10.1016/j.jogoh.2021.102228. Epub 2021 Sep 11. PubMed 34520877 ↗
  • Bulun SE. Endometriosis. N Engl J Med. 2009 Jan 15;360(3):268-79. doi: 10.1056/NEJMra0804690. No abstract available. PubMed 19144942 ↗
  • Chapron C, Marcellin L, Borghese B, Santulli P. Rethinking mechanisms, diagnosis and management of endometriosis. Nat Rev Endocrinol. 2019 Nov;15(11):666-682. doi: 10.1038/s41574-019-0245-z. Epub 2019 Sep 5. PubMed 31488888 ↗
  • Chapron C, Tosti C, Marcellin L, Bourdon M, Lafay-Pillet MC, Millischer AE, Streuli I, Borghese B, Petraglia F, Santulli P. Relationship between the magnetic resonance imaging appearance of adenomyosis and endometriosis phenotypes. Hum Reprod. 2017 Jul 1;32(7):1393-1401. doi: 10.1093/humrep/dex088. PubMed 28510724 ↗
  • Chapron C, Vannuccini S, Santulli P, Abrao MS, Carmona F, Fraser IS, Gordts S, Guo SW, Just PA, Noel JC, Pistofidis G, Van den Bosch T, Petraglia F. Diagnosing adenomyosis: an integrated clinical and imaging approach. Hum Reprod Update. 2020 Apr 15;26(3):392-411. doi: 10.1093/humupd/dmz049. PubMed 32097456 ↗
  • Di Donato N, Montanari G, Benfenati A, Leonardi D, Bertoldo V, Monti G, Raimondo D, Seracchioli R. Prevalence of adenomyosis in women undergoing surgery for endometriosis. Eur J Obstet Gynecol Reprod Biol. 2014 Oct;181:289-93. doi: 10.1016/j.ejogrb.2014.08.016. Epub 2014 Aug 15. PubMed 25201608 ↗
  • Eisenberg VH, Arbib N, Schiff E, Goldenberg M, Seidman DS, Soriano D. Sonographic Signs of Adenomyosis Are Prevalent in Women Undergoing Surgery for Endometriosis and May Suggest a Higher Risk of Infertility. Biomed Res Int. 2017;2017:8967803. doi: 10.1155/2017/8967803. Epub 2017 Sep 18. PubMed 29098162 ↗
  • Fauconnier A, Chapron C. Endometriosis and pelvic pain: epidemiological evidence of the relationship and implications. Hum Reprod Update. 2005 Nov-Dec;11(6):595-606. doi: 10.1093/humupd/dmi029. Epub 2005 Sep 19. PubMed 16172113 ↗
  • Giudice LC, Kao LC. Endometriosis. Lancet. 2004 Nov 13-19;364(9447):1789-99. doi: 10.1016/S0140-6736(04)17403-5. PubMed 15541453 ↗
  • Harmsen MJ, Van den Bosch T, de Leeuw RA, Dueholm M, Exacoustos C, Valentin L, Hehenkamp WJK, Groenman F, De Bruyn C, Rasmussen C, Lazzeri L, Jokubkiene L, Jurkovic D, Naftalin J, Tellum T, Bourne T, Timmerman D, Huirne JAF. Consensus on revised definitions of Morphological Uterus Sonographic Assessment (MUSA) features of adenomyosis: results of modified Delphi procedure. Ultrasound Obstet Gynecol. 2022 Jul;60(1):118-131. doi: 10.1002/uog.24786. PubMed 34587658 ↗
  • Hudelist G, Fritzer N, Thomas A, Niehues C, Oppelt P, Haas D, Tammaa A, Salzer H. Diagnostic delay for endometriosis in Austria and Germany: causes and possible consequences. Hum Reprod. 2012 Dec;27(12):3412-6. doi: 10.1093/humrep/des316. Epub 2012 Sep 17. PubMed 22990516 ↗
  • Khan KN, Fujishita A, Koshiba A, Kuroboshi H, Mori T, Ogi H, Itoh K, Nakashima M, Kitawaki J. Biological differences between intrinsic and extrinsic adenomyosis with coexisting deep infiltrating endometriosis. Reprod Biomed Online. 2019 Aug;39(2):343-353. doi: 10.1016/j.rbmo.2019.03.210. Epub 2019 Mar 27. PubMed 31160242 ↗
  • Kunz G, Beil D, Huppert P, Noe M, Kissler S, Leyendecker G. Adenomyosis in endometriosis--prevalence and impact on fertility. Evidence from magnetic resonance imaging. Hum Reprod. 2005 Aug;20(8):2309-16. doi: 10.1093/humrep/dei021. Epub 2005 May 26. PubMed 15919780 ↗
  • Leyendecker G, Bilgicyildirim A, Inacker M, Stalf T, Huppert P, Mall G, Bottcher B, Wildt L. Adenomyosis and endometriosis. Re-visiting their association and further insights into the mechanisms of auto-traumatisation. An MRI study. Arch Gynecol Obstet. 2015 Apr;291(4):917-32. doi: 10.1007/s00404-014-3437-8. Epub 2014 Sep 21. PubMed 25241270 ↗
  • Moradi Y, Shams-Beyranvand M, Khateri S, Gharahjeh S, Tehrani S, Varse F, Tiyuri A, Najmi Z. A systematic review on the prevalence of endometriosis in women. Indian J Med Res. 2021 Mar;154(3):446-454. doi: 10.4103/ijmr.IJMR_817_18. PubMed 35345070 ↗
  • Morassutto C, Monasta L, Ricci G, Barbone F, Ronfani L. Incidence and Estimated Prevalence of Endometriosis and Adenomyosis in Northeast Italy: A Data Linkage Study. PLoS One. 2016 Apr 21;11(4):e0154227. doi: 10.1371/journal.pone.0154227. eCollection 2016. PubMed 27101396 ↗
  • Naftalin J, Hoo W, Pateman K, Mavrelos D, Holland T, Jurkovic D. How common is adenomyosis? A prospective study of prevalence using transvaginal ultrasound in a gynaecology clinic. Hum Reprod. 2012 Dec;27(12):3432-9. doi: 10.1093/humrep/des332. Epub 2012 Sep 20. PubMed 23001775 ↗
  • Pinzauti S, Lazzeri L, Tosti C, Centini G, Orlandini C, Luisi S, Zupi E, Exacoustos C, Petraglia F. Transvaginal sonographic features of diffuse adenomyosis in 18-30-year-old nulligravid women without endometriosis: association with symptoms. Ultrasound Obstet Gynecol. 2015 Dec;46(6):730-6. doi: 10.1002/uog.14834. PubMed 25728241 ↗
  • Shigesi N, Kvaskoff M, Kirtley S, Feng Q, Fang H, Knight JC, Missmer SA, Rahmioglu N, Zondervan KT, Becker CM. The association between endometriosis and autoimmune diseases: a systematic review and meta-analysis. Hum Reprod Update. 2019 Jul 1;25(4):486-503. doi: 10.1093/humupd/dmz014. PubMed 31260048 ↗
  • Van den Bosch T, Dueholm M, Leone FP, Valentin L, Rasmussen CK, Votino A, Van Schoubroeck D, Landolfo C, Installe AJ, Guerriero S, Exacoustos C, Gordts S, Benacerraf B, D'Hooghe T, De Moor B, Brolmann H, Goldstein S, Epstein E, Bourne T, Timmerman D. Terms, definitions and measurements to describe sonographic features of myometrium and uterine masses: a consensus opinion from the Morphological Uterus Sonographic Assessment (MUSA) group. Ultrasound Obstet Gynecol. 2015 Sep;46(3):284-98. doi: 10.1002/uog.14806. Epub 2015 Aug 10. PubMed 25652685 ↗
  • Vercellini P, Vigano P, Somigliana E, Daguati R, Abbiati A, Fedele L. Adenomyosis: epidemiological factors. Best Pract Res Clin Obstet Gynaecol. 2006 Aug;20(4):465-77. doi: 10.1016/j.bpobgyn.2006.01.017. Epub 2006 Mar 24. PubMed 16563868 ↗
  • Yu O, Schulze-Rath R, Grafton J, Hansen K, Scholes D, Reed SD. Adenomyosis incidence, prevalence and treatment: United States population-based study 2006-2015. Am J Obstet Gynecol. 2020 Jul;223(1):94.e1-94.e10. doi: 10.1016/j.ajog.2020.01.016. Epub 2020 Jan 15. PubMed 31954156 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Jul 2027, 39 months after the start.

Of 158 non-industry observational studies under Endometriosis, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 48. This study's planned 39 months is above that.

Counting every sponsor, half of 185 studies reached it within 30 months; a quarter within 14 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2024
First posted
Jan 18, 2024
StartActual
Apr 4, 2024
Primary completionEst.
Jul 2027
CompletionEst.
Jan 2028
Last update
Apr 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06211569
Collaborators
URC-CIC Paris Descartes Necker Cochin
Responsible party
Sponsor
First posted
Jan 18, 2024
Start date
Apr 4, 2024
Primary completion
Jul 2027 (estimated)
Completion
Jan 2028 (estimated)
Last update
Apr 16, 2026

Study contacts

Mathilde BOURDON, MD
Contact
mathilde.bourdon@aphp.fr
00331 58 41 39 20
Marie Benhammani-Godard
Contact
marie.godard@aphp.fr
0033158411190

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion